^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    APOB (Apolipoprotein B)

    i
    Other names: APOB, Apolipoprotein B, Apolipoprotein B (Including Ag(X) Antigen), Apolipoprotein B-100, Apolipoprotein B48, Apo B-100, ApoB-100, ApoB-48, LDLCQ4, FCHL2, FLDB
    3d
    Effects of Replacing High Protein Foods in People With Chronic Kidney Disease (clinicaltrials.gov)
    P=N/A, N=15, Not yet recruiting, Indiana University | Trial completion date: Jun 2026 --> Jun 2027 | Initiation date: Jan 2026 --> May 2026 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    APOB (Apolipoprotein B)
    4d
    Food Allergy-Induced Systemic Immune Alterations Affect Tumor Progression in a CT26 Colon Adenocarcinoma Mouse Model. (PubMed, Allergy)
    This study establishes a practical in vivo model for AllergoOncology and demonstrates that systemic allergic responses can modulate tumor progression through immune activation, apoptosis, and inflammation-metabolism axis reprogramming, providing a foundation for future mechanistic and therapeutic studies.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • APOB (Apolipoprotein B) • ACTA1 (Actin Alpha 1, Skeletal Muscle)
    10d
    Mediterranean Diet and Blood Sugar Study (clinicaltrials.gov)
    P=N/A, N=74, Not yet recruiting, Penn State University | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    |
    APOB (Apolipoprotein B)
    11d
    First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics (clinicaltrials.gov)
    P1, N=104, Not yet recruiting, SUNHO（China）BioPharmaceutical CO., Ltd.
    New P1 trial • First-in-human
    |
    APOB (Apolipoprotein B)
    13d
    A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia (clinicaltrials.gov)
    P1, N=96, Active, not recruiting, AstraZeneca | Trial primary completion date: Aug 2026 --> Dec 2025
    Trial primary completion date
    |
    APOB (Apolipoprotein B)
    16d
    Target of Suv420h1/2 in Hepatocytes (clinicaltrials.gov)
    P=N/A, N=260, Recruiting, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Trial primary completion date: Feb 2026 --> Sep 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • APOB (Apolipoprotein B) • PNPLA3 (Patatin Like Phospholipase Domain Containing 3)
    18d
    Very low-density lipoprotein and the human health. (PubMed, World J Exp Med)
    Aside from this, VLDL metabolism and carcinogenesis might be altered by the VLDL receptor. Overall, growing findings point to the role of VLDL in many illnesses.
    Review • Journal
    |
    APOB (Apolipoprotein B)
    19d
    Omics analysis of the regulatory role of APOBEC in the immune microenvironment of head and neck squamous cell carcinoma with different HPV status (PubMed, Zhonghua Zhong Liu Za Zhi)
    APOBEC exhibits distinct driving mechanisms in HNSCC depending on HPV status. Its activity is closely related to cGAS-STING pathway activation, enhanced immune infiltration, and improved immunotherapy efficacy, suggesting potential predictive and therapeutic value.
    Journal • IO biomarker
    |
    APOB (Apolipoprotein B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
    19d
    Correlation study of blood lipid indexes and body mass index with clinical characteristics of cervical squamous cell carcinoma (PubMed, Zhonghua Fu Chan Ke Za Zhi)
    There were no significant differences in lipid indexes among CSCC patients with different depth of myometrial invasion, lymphovascular space invasion or not, and parametrial invasion or not (all P>0.05). BMI combined with ApoB/ApoA1 ratio might be used as a potential indicator to evaluate the severity of cervical lesions and to predict lymph node metastasis.
    Retrospective data • Journal
    |
    APOA1 (Apolipoprotein A-I) • APOB (Apolipoprotein B)
    19d
    Genomic profiling of meiotic errors and early malignant transformation events in ovarian mature teratoma. (PubMed, Reproduction)
    Mutational signature analysis showed enrichment of apolipoprotein B mRNA editing enzyme catalytic subunit-associated signatures. This study suggests novel perspectives on the mechanisms of OMT tumor development and malignant transformation.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • APOB (Apolipoprotein B)
    |
    TP53 mutation • PIK3CA mutation • TMB-L
    19d
    A Dose-exploration Study of EDP167 in HoFH (clinicaltrials.gov)
    P2, N=20, Recruiting, Eddingpharm (Zhuhai) Co., Ltd.
    New P2 trial
    |
    APOB (Apolipoprotein B)
    20d
    SHASTA-10: Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (clinicaltrials.gov)
    P3, N=869, Recruiting, Arrowhead Pharmaceuticals | N=334 --> 869
    Enrollment change
    |
    APOB (Apolipoprotein B)